BMS-986318

BMS-986318 is a potent, orally administered, nonbile acid small molecule agonist of the farnesoid X receptor (FXR), a nuclear hormone receptor involved in bile acid regulation and metabolic homeostasis. It was developed by Bristol Myers Squibb for the treatment of liver diseases such as nonalcoholic steatohepatitis (NASH), liver cholestasis, and fibrosis. Preclinical studies demonstrated that BMS-986318 activates FXR both in vitro and in vivo, showing efficacy in mouse models of liver cholestasis and fibrosis with favorable ADME properties. The compound is designed to offer an alternative to bile acid-derived FXR agonists, potentially reducing adverse effects like hepatotoxicity and pruritus observed with other agents[1][5][6][7].